SCM
AQST icon

Sterling Capital Management’s Aquestive Therapeutics AQST Stock Holding History

Sterling Capital Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.2K Sell
2,460
-1,659
-40% -$6.73K ﹤0.01% 2363
2025
Q4 		$26.6K Buy
4,119
+119
+3% +$742 ﹤0.01% 2077
2025
Q3 		$22.4K Buy
4,000
+2,426
+154% +$10.5K ﹤0.01% 2089
2025
Q2 		$5.21K Buy
1,574
+620
+65% +$1.78K ﹤0.01% 2490
2025
Q1 		$2.77K Sell
954
-799
-46% -$2.42K ﹤0.01% 2451
2024
Q4 		$6.24K Buy
1,753
+1,560
+808% +$7.19K ﹤0.01% 2358
2024
Q3 		$961 Buy
+193
New +$751 ﹤0.01% 2551

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Sterling Capital Management's AQST Position: Q1 2026 in Review

Sterling Capital Management reduced its Aquestive Therapeutics (AQST) stake by 40% in Q1 2026, selling an estimated $6.73K and leaving 2,460 shares worth $10.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2363.

Sterling Capital Management first reported a position in AQST in Q3 2024 and has held it in 7 quarters since. The position peaked at $26.6K in Q4 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Sterling Capital Management held 2,460 shares of Aquestive Therapeutics worth $10.2K as of Q1 2026.
  • Sterling Capital Management sold 1,659 Aquestive Therapeutics shares in Q1 2026, an estimated $6.73K.
  • Aquestive Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #2363 holding.
  • Sterling Capital Management first reported a position in Aquestive Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Sterling Capital Management's Aquestive Therapeutics position peaked at $26.6K in Q4 2025.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.